Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation:
Evidence-based clinical science should guide FDA decision making about product labeling
To access this article, please choose from the options below
PII: S0010-7824(06)00034-5
doi:10.1016/j.contraception.2006.01.007
© 2006 Elsevier Inc. All rights reserved.
